Actinium Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Actinium Pharmaceuticals, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Actinium Pharmaceuticals has little or no product revenue yet; it used $23m of cash in the twelve months to June 2026. It passes 2 of our 2 financial-health checks.
Our model value for Actinium Pharmaceuticals is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 545% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Actinium Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.25 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | ~$3.3 ~$2.7–$7.6 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Actinium Pharmaceuticals, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|
| Share price | $6.01 | $10.65 | $5.08 | $1.36 |
| Market value | $124m | $257m | $135m | $42m |
| + Net debt (− = net cash) | −$72m | −$99m | −$69m | −$48m |
| Enterprise value | $51m | $158m | $66m | −$6m |
| Multiples | ||||
| Price / sales | 108.1x | n/m | n/m | n/m |
| Price / earnings | — | — | — | — |
| Price / free cash flow | — | 31.1x | — | — |
| EV / EBITDA | — | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $0.14 | +113% | $35m | +38789% |
| Next | −$0.53 | −475% | — | −100% |
The consensus EPS forecast for the current fiscal year is −115.4% on 90 days ago. In the last 30 days, 0 analysts raised Actinium Pharmaceuticals, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.91 | −$0.35 |
| 60 days ago | $0.14 | −$0.53 |
| 30 days ago | $0.14 | −$0.53 |
| 7 days ago | $0.14 | −$0.53 |
| Now | $0.14 | −$0.53 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.20 | $0.89 | +545.0% |
| Mar 2026 | −$0.22 | −$0.18 | +18.2% |
| Dec 2025 | −$0.19 | −$0.19 | −1.8% |
| Sept 2025 | −$0.32 | −$0.16 | +50.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ATNM | −23% | +77% | −52% | −75% | +8% | +5% |
| Industry peers (median) | −36% | −57% | −17% | −28% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ATNM | 42% | 42% | 17% | 25% | 33% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ATNM | −41% | −34% | −72% | −89% | −39% | −51% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 99% from January 4, 2016 to August 5, 2026. Getting back needed a 13518% gain, and the shares have not yet recovered.
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY12 Q1 | $0 |
| FY12 Q2 | $0 |
| FY12 Q3 | $0 |
| FY21 Q4 | $1.1M |
| FY22 Q1 | $1.5M |
| FY22 Q2 | $1.2M |
| FY22 Q3 | $1.1M |
| FY22 Q4 | $1M |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY21 Q4 | -2182.2% |
| FY22 Q1 | -1693.3% |
| FY22 Q2 | -2218.5% |
| FY22 Q3 | -2930.8% |
| FY22 Q4 | -3311.1% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY21 Q4 | -1835.6% |
| FY22 Q1 | -1446.0% |
| FY22 Q2 | 898.6% |
| FY22 Q3 | 1046.5% |
| FY22 Q4 | 803.7% |
| Fiscal year | 2010 Dec 2010 | 2011 Dec 2011 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|
| Income | ||||||
| Revenue | 0 | 0 | 1 | 1 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | — | — | — |
| EBITDA | — | −3 | −24 | −33 | −52 | −36 |
| Operating income | −0 | −3 | −25 | −34 | −52 | −36 |
| Net income | −0 | −3 | −25 | −33 | −49 | −34 |
| Diluted EPS | $0.01 | −$129.00 | −$1.20 | −$1.37 | −$1.83 | −$1.09 |
| Growth (year on year) | ||||||
| Revenue | — | — | — | −10.0% | −92.1% | +11.1% |
| Diluted EPS | — | <−999% | — | — | — | — |
| Margins | ||||||
| Gross margin | — | — | 21.3% | — | — | — |
| EBITDA margin | — | — | <−999% | <−999% | <−999% | <−999% |
| Operating margin | — | — | <−999% | <−999% | <−999% | <−999% |
| Net margin | — | — | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | — | — | <−999% | 803.7% | <−999% | <−999% |
| Cash flow | ||||||
| Cash from operations | 0 | −1 | −21 | 9 | −47 | −25 |
| Capital spending | — | — | 0 | 0 | 0 | 0 |
| Free cash flow | — | — | −21 | 8 | −47 | −25 |
| Stock-based pay | 0 | 2 | 2 | 3 | 4 | 9 |
| Free cash flow after stock pay | — | — | −23 | 5 | −51 | −34 |
| Balance sheet | ||||||
| Cash | 0 | 6 | 78 | 109 | 77 | 48 |
| Total debt | 0 | 0 | 6 | 10 | 8 | 0 |
| Net debt (negative = net cash) | −0 | −6 | −72 | −99 | −69 | −48 |
| Diluted shares | — | — | 21m | 24m | 27m | 31m |
| Quarter | 2021 Q4 Dec 2021 | 2022 Q1 Mar 2022 | 2022 Q2 Jun 2022 | 2022 Q3 Sept 2022 | 2022 Q4 Dec 2022 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 35 |
| EBITDA | −8 | −5 | −8 | −10 | −11 | −5 | −7 | 28 |
| Operating income | −8 | −5 | −8 | −10 | −11 | −6 | −6 | 28 |
| Net income | −8 | −5 | −8 | −9 | −11 | −5 | −6 | 28 |
| Diluted EPS | −$0.36 | −$0.23 | −$0.33 | −$0.38 | −$0.43 | −$0.16 | −$0.19 | $0.89 |
| Growth (year on year) | ||||||||
| Revenue | — | +51.1% | −83.1% | −80.7% | −100.0% | — | — | — |
| Margins | ||||||||
| EBITDA margin | <−999% | −534.8% | <−999% | <−999% | — | <−999% | — | 80.0% |
| Operating margin | <−999% | −549.4% | <−999% | <−999% | — | <−999% | — | 78.8% |
| Net margin | <−999% | −545.6% | <−999% | <−999% | — | <−999% | — | 79.7% |
| Free-cash-flow margin | <−999% | −615.7% | >999% | <−999% | — | — | — | −16.2% |
| Cash flow | ||||||||
| Cash from operations | −5 | −6 | 28 | −6 | −8 | −6 | −5 | −5 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Free cash flow | −5 | −6 | 28 | −6 | −8 | — | — | −6 |
| Stock-based pay | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Free cash flow after stock pay | −6 | −6 | 27 | −7 | −9 | — | — | −6 |
| Last 12 months unless stated | ATNM | STTK | MNOV | LGVN | DARE | RNAC | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $1m | $1m | $920481 | $1m | $1m | $1m | $55m |
| Revenue growth, last 12 months | −10.0% | −66.6% | 875.7% | −42.7% | >999% | 44.0% | 12.2% |
| Revenue growth, 3-year average | — | 5.2% | — | 10.4% | — | −68.8% | 13.7% |
| Revenue growth, latest quarter | −100.0% | −66.6% | 240.6% | −9.2% | 499.6% | −100.0% | 10.2% |
| Gross margin | — | — | 100.0% | 69.8% | — | — | 82.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | −813.4% | <−999% | −191.1% |
| Operating margin, 3-year average | — | <−999% | −905.8% | <−999% | >999% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | −804.4% | <−999% | −172.8% |
| Cash from operations / revenue | 839.2% | <−999% | −989.7% | <−999% | −826.8% | <−999% | −162.3% |
| Free-cash-flow margin | 803.7% | <−999% | −991.2% | <−999% | −860.6% | <−999% | −156.7% |
| Free-cash-flow margin, 3-year average | — | <−999% | <−999% | <−999% | >999% | <−999% | −310.0% |
| Stock pay / revenue | 271.4% | 853.2% | 100.3% | 132.8% | 110.0% | 625.6% | 20.7% |
| Change in share count | 0.3% | 15.3% | 0.2% | — | 62.5% | 143.3% | 8.1% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Vanguard Capital Management LLC | $1.2M | 1.2M | 23.4% | ▼ 1.4% |
| Compass Financial Management LLC | $588,225 | 600K | 11.3% | — |
| Millennium Management LLC | $504,288 | 515K | 9.7% | ▼ 8.9% |
| Acadian Asset Management LLC | $485,000 | 496K | 9.4% | ▼ 17.4% |
| Blackrock, Inc. | $387,978 | 396K | 7.5% | ▲ 6.7% |
| Renaissance Technologies LLC | $372,881 | 380K | 7.2% | ▼ 19.3% |
| Geode Capital Management, LLC | $318,553 | 325K | 6.1% | ▼ 3.3% |
| Two Sigma Investments, LP | $253,995 | 259K | 4.9% | ▼ 23.1% |
| Gagnon Securities LLC | $178,499 | 182K | 3.4% | ▼ 9.5% |
| Vanguard Fiduciary Trust Co | $158,295 | 162K | 3.1% | ▲ 0.8% |
| State Street Corp | $119,771 | 122K | 2.3% | ▼ 3.2% |
| Gen-Wealth Partners Inc | $103,009 | 105K | 2.0% | ▼ 1.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Actinium Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
